617 results about "Human papilloma virus" patented technology

Vectors for DNA immunization against cervical cancer comprise a nucleic acid molecule encoding at least one non-toxic T-cell epitope of the E6 and / or E7 antigens of a strain of human papilloma virus (HPV) associated with cervical cancer, such as HPV-16, and a promoter operatively coupled to the nucleic acid molecule for expression of the nucleic acid molecule in a host to which the vector is administered.

The invention provides a construction method of a human papilloma virus resistant HPV polyvalent vaccine and application thereof.

The present invention comprises, without limitation, systems, methods, and compositions for the detection, identification, and quantification, down to the single copy level, of human papillomavirus (HPV) in biological samples, including but not limited to, mammalian body fluids and cervix scrapings, for purposes of detection, treatment and / or management of cancer and dysplasia.

The invention provides an sgRNA combined with immunogene to inhibit high risk HPV expression, a gene knockout vector thereof, and an application of the sgRNA and the vector. The sgRNA sequences of a human papilloma virus 16 type gene suitable for CRISPR-Cas9 targeting editing and a human PD-1 gene are selected, and the plasmid vector of the sgRNA and a CRISPR-Cas9 nuclease gene expression vector are transferred to HPV16+ human cervical carcinoma cells and HPV16+ transplantation tumor-bearing mice, and can obviously inhibit HPV16 expression and inhibit tumor growth. The gene expression vector prepared in the invention has the advantages of simple method steps, good sgRNA targeting property, high CRISPR-Cas9 knockout efficiency, accurate targeting splicing of high risk HPV16 type and PD-1 genes, efficient reduction of the expression of the high risk HPV16 type gene, and obvious inhibition of the tumor growth through combined application.

Topically applied transdermally quick penetrating (best targeting the epidermis and subsequently remaining there for a prolonged period of time) systemic independent acting, combinations and formulations which employ, combine, or incorporate a therapeutically effective non-toxic (to the patient) amount of a drug which inhibits prostaglandin synthesis together with an amount of hyaluronic acid and / or salts thereof (for example the sodium salt) and / or homologues, analogues, derivatives, complexes, esters, fragments, and / or sub units of hyaluronic acid to treat a disease and condition of the skin and exposed tissue for example, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women and remain in the skin for a prolonged period of time.

The invention relates to an amino acid sequence of a recombinant human papillomavirus L1 capsid protein, a nucleotide sequence which encodes the amino acid sequence and a recombinant vector and an expression host which contain the nucleotide sequence. The invention further relates to an application of a HPV L1 protein which is composed of the amino acid sequence in the preparation of vaccines, drug combination and diagnostic antigens or antibodies. The invention allows the recombinant HPV L1 capsid protein which is expressed in a prokaryotic system to be dissolvable in water by the modification of the HPV L1 wild-type sequence, and an L1 pentamer which has the same immunogenicity and antigenicity with the VLP of HPV L1 is obtained by expression. The invention allows the industrial production of the HPV L1 capsid protein by utilizing the prokaryotic expression system to become a reality, compared with the currently used eukaryotic expression system, the invention has the advantages of more stable quality of the products, higher yield, low cost and convenient quality control, which has great economic benefits and social effects.

The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen. The immunogenic peptide compositions of the present invention comprise immunogenic peptides having an HLA binding motif, where the peptide is from a target antigen. Target antigens of the present invention include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e.g., MAGE-1), human immunodeficiency virus (HIV) antigens, human papilloma virus (HPV) antigens, Lassa virus, mycobacterium tuberculosis (MT), p53, CEA, trypanosome surface antigen (TSA) and Her2 / neu. An example of an immunogenic peptide of the present invention corresponds to a peptide less than about 15 amino acids in length that comprises an HLA-A2.1 binding motif, where the peptide comprises the p53 sequence SMPPPGTRV.

The invention discloses a primer, a probe and a kit for fluorescence PCR (Polymerase Chain Reaction) detection of 18 types of high-risk human papilloma viruses. Different typing kits are detected by adding different specificity probes; the DNAs (Deoxyribose Nucleic Acids)) of 18 types of common high-risk human papilloma viruses internationally recognized and closely related to the cervical cancer can be detected once; and typing detection is carried out on HPV (Human Papilloma Virus)16 and 18. The application provides 6 universal primers and 18 specific molecular beacon probes. The DNAs of the 18 types of common high-risk human papilloma viruses can be amplified by the 6 universal primers; and meanwhile, the 18 probes are the specific molecular beacon probes designed by aiming at the 18 high-risk types; different types of probes are added according to the detection need and combined as the kits aiming at the detection need of the different high-risk types; and at the same time, the added probes are marked by different report genes, so that the purpose of carrying out typing detection on the high-risk HPV is achieved.

The present invention relates to compositions and methods of treating warts and other human papilloma virus (HPV) skin infections. The present invention relates to compositions and methods of treating skin cancer.

The invention belongs to the technical field of medicines, and discloses a gel and a use thereof. The gel comprises a chitosan polymer, a hyaluronic acid matter, a lactic acid matter, a gel matrix, a wetting agent and a diluter. The gel has the advantages of good antibacterial effect, wide antibacterial spectrum (comprising high risk HPV (Human Papilloma Virus), physical antibacterial effect, no tolerance, biodegradability, safety and environment-friendliness and lasting effect for a long time, and has the functions of nourishing, lubricating, whitening, repairing skins or mucosal tissues, and removing spots and inhibiting cicatrisation for skins or mucosal tissues.

The invention discloses a method to increase human papilloma virus L1 protein pronucleus expression productivity and also discloses a encode HPV L1 protein codon majorizing nucleic acid sequence from this method, which is characterized by the following: supplying expression carrier and host cell and HPVL1 protein poly body of nucleic acid sequence; disclosing appliance in preparing vaccine, drug compound and immunodiagnosis or antibody. The nucleic acid sequence expressing quantity possesses distinctive improvement, which decreases the preparing cost effectively.

An assay for detecting HPV comprising treating the viral nucleic acid with an agent that modifies cytosine to form derivative viral nucleic acid, amplifying at least a part of the derivative viral nucleic acid to form an HPV-specific nucleic acid molecule, and looking for the presence of an HPV-specific nucleic acid molecule, wherein detection of the HPV-specific nucleic acid molecule is indicative HPV.

Topical drug compositions of this invention contain delayed type contact sensitizing haptens in a unique non-flowable, non-toxic, non-volatile, anhydrous gel composition to achieve retained site application on warts and other human papilloma virus (HPV) skin infections. The preferred gelled compositions contain, but are not limited to, the sensitizing haptens, squaric acid dibutylester and diphenylcyclopropenone in optimized blends of Polysorbate 80, Isopropyl myristate uniquely gelled with Polyoxyl 40 stearate to form a penetrant of keratinized epitheliiuim of warts for direct application wherein virucidal pharlacologic action is induced by Th-1 cell mediated immune responses with resultant releases of CD4 helper T cells, CD8 killer T cells and cytokines to attack the human papilloma viruses. The commonly used vehicles with these contact sensitizers are acetone, petrolatum, or water containing emulsion creams which do not have the capacity to penetrate the keratinized wart surfaces and are therefore minimally effective in treating warts.

The present invention provides a purification method of human papillomavirus late protein L1 from escherichia coli. Virus-like Particles; the virus-like Particles with elctrophoresis purity more than 98 percent can be produced in a large scale through salt free precipitation, re-dissolving, ion exchange chromatography, hydrophobic interaction chromatography and renaturation of the L1 protein in the lysate supernatant of escherichia coli. With good immunogenicity, the virus particles can induce neutralizing antibodies towards homologous HPV virus, and can be used as a vaccine for preventing the infection of HPV.

The invention relates to a method of screening for precursor lesions which can lead to cervical malignancy, methods of detecting and typing human papilloma virus infections, and reagents of use in these methods.

Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV 6, HPV 11, HPV 33 and HPV58 E6 and E7. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.

Genetic vaccines and methods are provided for enhancing the immunity of a host such as a human to one or more pathogens. In one aspect, a method of enhancing the immunity of a host to a pathogen is provided. The method comprises administering to the host a recombinant virus comprising an antigen sequence that is heterologous to a native progenitor of the recombinant adenovirus and encodes a viral antigen from a pathogenic virus, expression of which is under the transcriptional control of a first promoter; and a cytokine sequence that is heterologous to the native progenitor of the recombinant adenovirus and encodes a cytokine, expression of which is under the transcriptional control of a second promoter. Expression of the antigen and cytokine sequences elicits an immune response directed against the viral antigen upon infection of the host by the recombinant virus. The method can be used for immunizing a host against a wide variety of pathogen viruses, such as HIV, Ebola virus, Marburg virus, hepatitis B virus, hepatitis C virus, influenza virus, human simplex virus, human papilloma virus and respiratory syncytial virus.

The invention discloses a preparation method for a biological agent for preventing and controlling human papilloma virus infection. The preparation method includes following steps: dissolving 3-hydroxy-phthalic anhydride HP into dimethyl sulfoxide DMSO to obtain saturated HP solution; dissolving beta-lactoglobulin beta-LG into 0.1M of sodium phosphate solution with pH (potential of hydrogen) of 8.5 to obtain protein solution with protein final concentration of 20mg / mL; and equally dividing the HP solution into five parts, adding the HP solution into the protein solution at every 12 minutes, shaking and mixing, adjusting pH of IMNaOH to be 8.5, leading the final concentration of anhydride in a reaction system to be 60mM, standing for 1 hour at the temperature of 25 DEG C, dialyzing by PBS (phosphate buffer solution) with pH of 7.4, performing filtration sterilization by a 0.45uM microfiltration membrane, and storing at the temperature of 4 DEG C so as to obtain a finished product. The biological agent has the advantages of capabilities of stopping HPV (human papilloma virus) from invading cells and stopping virus infection from spreading, safety, stability, low cost and the like.

The invention relates to truncated L1 proteins of a human papilloma virus (HPV), virus-like particles as well as a preparation method and application of virus-like particles. The invention particularly relates to HPV6-type, HPV11-type, HPV16-type, HPV18-type or HPV58-type truncated L1 proteins of the HPV, the virus-like particles as well as the preparation method and application of the virus-like particles.

The invention relates to monoclonal antibodies and antigen binding fragments thereof, which can have a broad spectrum combination with human papilloma virus (HPV) L1 protein, coding of the sequences of the monoclonal antibodies and the antigen binding fragments thereof, generation of cell strains of the monoclonal antibodies and the antigen binding fragments thereof, and methods and applications of the monoclonal antibodies and the antigen binding fragments thereof on diagnosis, prevention or treatment.

The invention provides a high accuracy detection method of human papilloma virus genotype. Double probe, which comprises a carcinogenicity early transcription region E6 or E7 gene region and a capsid protein late transcription region L1 or L2 gene region, is adopted to detect every genotype. According to the method, pollution exclusion of PCR amplification product is taken as a premise, identical genotype recognition by double gene probe is taken as a basis, and high sensitivity PCR-mass spectrum combination is taken as a platform. The invention provides a method for high accuracy detection and / or identification of human papilloma virus (HPV) genotype.

The invention relates to a human papilloma virus 18 L1 (HPV18L1) polynucleotide sequence and its expression vector, host cell and use and especially relates to an amino acid sequence of an HPV L1 capsid protein, a synthetic nucleotide sequence for coding the amino acid sequence, a recombinant expression vector containing the synthetic nucleotide sequence, and a hansenula polymorpha expression host strain containing the synthetic nucleotide sequence. The invention also relates to a use of an HPV18L1 protein composed of the amino acid sequence and derivatives of the amino acid sequence in preparation of vaccines. Through modification of a nucleotide sequence of a gene of an HPV18L1 wide-type virus, a recombinant HPV18L1 capsid protein can be highly expressed in a hansenula polymorpha expression system and thus hansenula polymorpha expression system-based industrial production of an HPV18L1 capsid protein is realized. Compared with the existing eukaryotic expression systems, the HPV18L1 polynucleotide sequence and its expression vector and host cell have advantages of higher yield and lower cost.

The invention belongs to the field of cell biology, relating to a cell preserving fluid and a preparation method and use thereof. Concretely, the cell preserving fluid comprises a fixing agent, a fixing agent assistant, an anticoagulant, a cushion fluid and an ionic strength maintenance agent. The cell preserving fluid is characterized in that the content of the anticoagulant is 0.01% to 1.5%(w / w); the content of the ionic strength maintenance agent is 0.01% to 1%(w / w); and the cell preserving fluid does not contain a disulfide bond open reagent. The cell preserving fluid can effectively preserve cell DNA (deoxyribonucleic acid) and virus DNA infecting the cell, is convenient to collect the cast-off cells and extract DNA and can give attention to storage of the cell structure. The invention also relates to the preparation method and the use of the cell preserving fluid. The invention also relates to a kit and a method for detecting HPV (Human Papilloma Virus) or HPV DNA.

The invention relates to a polypeptide, in particular to a human papilloma virus coat protein L1 short peptide and relative application. The invention is characterized in that the sequence of the human papilloma virus coat protein L1 short peptide is N-EVNLKEKFSADLDQFPLGRKFLLQAGLKAK-C. The invention can simultaneously induce human papilloma virus coat protein L1 short peptide with immunity reaction on high risk type and low risk type, which can induce and form the antibody for various human papilloma virus (HPV) and coat protein (HPV L1), to check various HPV or HPV L1, while the antibody can be used in biological pharmaceutical engineering, to purify and prepare various HPV or HPV L1.

The invention discloses a graphene modified natural emulsion preparation method and a high barrier condom. The graphene modified natural emulsion preparation method and the high barrier condom have the beneficial effects that firstly graphene and a dispersing agent mixed liquor are mixed, ground and stirred and then the product is mixed in a natural emulsion aqueous solution, so that graphene can be uniformly dispersed in emulsion and the strength of a natural emulsion composite material is improved; meanwhile, the number of micropores is smaller due to the graphene / emulsion composite action, thus greatly reducing the virus penetration probability; the thickness of the graphene condom can be 5-80mu m, so that the use requirements of the condom can be met; dense high barrier packing layers are formed by the composite crosslinked nano-packing technology, so that the natural gaps among molecules are reduced; therefore not only can HIVs be blocked but also hepatitis B viruses, hepatitis C viruses, human papilloma viruses, and the like, and most harmful bacteria, which are smaller than the HIVs, can not pass through the micropores.

A novel animal model for the treatment of skin tumors is described. In particular, the invention provides transgenic non-human animals comprising a recombinant nucleic acid molecule containing a nucleic acid sequence encoding at least one of the gene products of the early genes of a virus of the Human Papilloma Virus Group B1, in which the animal displays one or more clinical symptoms of a tumor. The transgenic animals can be used to screen anti-tumor agents and to identify the tumorigenic potential of compounds.